Neuvivo to Present at the 35th International Symposium on ALS/MND in Montreal, Canada, December 6-8, 2024

Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA

Significant Breakthroughs in Preserving ALS Lung Function and Survival Unveiled in Peer-Reviewed Studies of Novel Immunotherapy Platform NP001

Neuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment NP001

Neuvivo Announces Mark Henderson, PhD, as Vice President of Manufacturing to Support Technical Operations for Investigational ALS Treatment

Neuvivo Appoints Matthew W. Davis, MD, RPh, as New Chief Medical Officer to Continue Advancing Novel ALS Treatment

Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS

New Study of NP001 is First to Link Regulation of the Innate Immune System with Respiratory Function in ALS Patients

Neuvivo’s NP001 for Treatment of ALS Slows Disease Progression Through Regulation of Microbial Translocation

Neuvivo Adds Former FDA Chief Counsel Peter Barton Hutt as Advisor

Neuvivo’s NP001 – an Immune System Regulator – Has Effect on Biomarkers of Microbial Translocation in ALS Patients Responsive to Treatment

Neuvivo Closes on Additional Funding Round for NP001 Development

Neuvivo Begins Manufacturing of NP001 for Treatment of ALS

Neuvivo Announces Addition of Michael Snyder, PhD – Chair of the Department of Genetics at the Stanford School of Medicine – to Scientific Advisory Board

Neuvivo Adds James Kovach, MD, former NFL Player, and Current Executive Director of UC Davis Health Translational Entrepreneurship Program to Advisory Board

Neuvivo Announces Publication of Paper on ALS Drug Candidate NP001 in Peer-Reviewed Journal, Muscle & Nerve

Neuvivo Expands Management Team Adding Gregg Fergus, Former President of Ion Torrent, as Head of Strategy and Business Development and to the Board of Directors

Neuvivo Announces Filing of Type C Meeting Request with FDA Regarding Its Plans for Development and Marketing of NP001 for the Treatment of ALS

Neuvivo Launches to Develop and Market Effective and Safe Treatments for ALS